Warning
This is an unofficial archive of PsychonautWiki as of 2025-08-08T03:33:20Z. Content on this page may be outdated, incomplete, or inaccurate. Please refer to the original page for the most up-to-date information.

Talk:Aripiprazole: Difference between revisions

From PsychonautWiki Archive
Jump to navigation Jump to search
← Older editNewer edit →
>Theacidman
No edit summary
>Nibbablaster3000
m Will keep fixing it
Line 1: Line 1:
Aripiprazole (Abilify)


Aripiprazole is a atypical antipsychotic. It works by modulating serotonin and dopamine levels in the brain. <br />
{{SummarySheet}}
{{SubstanceBox/Aripiprazole}}
'''Aripiprazole''' (branded as '''Abilify''', '''Aristada''' among others) is an atypical [[psychoactive class::antipsychotic]] approved for the treatment of schizophrenia, psychosis, bipolar disorder, and along with an antidepressant to treat major depressive disorder.


hello please make this page
Aripiprazole was developed by "Ostuka-group" from Japan as an improvement from first-generation antipsychotics. The active molecule was originally found by the US based Bristol-Myers Squibb.


<br />
===Schizophrenia===
The 2016 [[NICE]] guidance for treating psychosis and schizophrenia in children and young people recommended aripiprazole as a second line treatment after [[risperidone]] for people between 15 and 17 who are having an acute exacerbation or recurrence of psychosis or schizophrenia.<ref>{{cite web |title=Psychosis and schizophrenia in children and young people: recognition and management {{!}} Guidance and guidelines {{!}} NICE |url=https://www.nice.org.uk/guidance/cg155/chapter/Recommendations |publisher=NICE |date=October 2016}}</ref> A 2014 NICE review of the depot formulation of the drug found that it might have a role in treatment as an alternative to other depot formulations of second generation antipsychotics for people who have trouble taking medication as directed or who prefer it.<ref>{{cite web |title=Schizophrenia: aripiprazole prolonged-release suspension for injection {{!}} Guidance and guidelines {{!}} NICE |url=https://www.nice.org.uk/advice/esnm39/chapter/Key-points-from-the-evidence |publisher=NICE |date=24 July 2013}}</ref>
 
==Adverse effects==
{{See also|List of adverse effects of aripiprazole}}
 
In adults, side effects with greater than 10% incidence include weight gain, headache, [[akathisia]], insomnia, and gastro-intestinal effects like nausea and constipation, and lightheadedness.<ref name = DM/><ref name = EMC/><ref name = EMA/><ref name = ABILIFY/><ref name="WebMD"/> Side effects in children are similar, and include sleepiness, increased appetite, and stuffy nose.<ref name = ABILIFY/> A strong desire to gamble, binge eat, shop, and engage in sexual activity may also occur.<ref name="FDA impulse control">{{cite web |date=3 May 2016 |title=Aripiprazole (Abilify, Abilify Maintena, Aristada): Drug Safety Communication - FDA Warns About New Impulse-control Problems |url=https://www.fda.gov/drugs/drug-safety-and-availability/fda-drug-safety-communication-fda-warns-about-new-impulse-control-problems-associated-mental-health |access-date=4 May 2016 |website=U.S. [[Food and Drug Administration]] (FDA)}}</ref><ref name="pmid26658263">{{cite journal | vauthors = Grall-Bronnec M, Sauvaget A, Perrouin F, Leboucher J, Etcheverrigaray F, Challet-Bouju G, Gaboriau L, Derkinderen P, Jolliet P, Victorri-Vigneau C | display-authors = 6 | title = Pathological Gambling Associated With Aripiprazole or Dopamine Replacement Therapy: Do Patients Share the Same Features? A Review | journal = Journal of Clinical Psychopharmacology | volume = 36 | issue = 1 | pages = 63–70 | date = February 2016 | pmid = 26658263 | pmc = 4700874 | doi = 10.1097/JCP.0000000000000444 }}</ref>
 
Uncontrolled movement such as restlessness, tremors, and muscle stiffness may occur.<ref name = ABILIFY/>  
 
There seems to be no recreational ways for using aripiprazole.

Revision as of 20:08, 7 November 2022

Summary sheet: Aripiprazole
Aripiprazole
Chemical Nomenclature
Common names Aripiprazole, Abilify
Systematic name [[systematic name::7-{4-[4-(2,3-Dichlorophenyl)piperazin-1-yl]butoxy}-3,4-dihydroquinolin-2(1H)-one]]
Routes of Administration

WARNING: Always start with lower doses due to differences between individual body weight, tolerance, metabolism, and personal sensitivity. See responsible use section.



⇣ Oral
Dosage
Bioavailability 87%[1]
Threshold 1 mg
Light 1 - 5 mg
Common 5 - 15 mg
Strong 15 - 30 mg
Heavy 30 mg +
Duration
Total 72 - 120 hours
Onset 30 - 60 minutes
Come up 3 - 5 hours









DISCLAIMER: PW's dosage information is gathered from users and resources for educational purposes only. It is not a recommendation and should be verified with other sources for accuracy.

Aripiprazole (branded as Abilify, Aristada among others) is an atypical antipsychotic approved for the treatment of schizophrenia, psychosis, bipolar disorder, and along with an antidepressant to treat major depressive disorder.

Aripiprazole was developed by "Ostuka-group" from Japan as an improvement from first-generation antipsychotics. The active molecule was originally found by the US based Bristol-Myers Squibb.

Schizophrenia

The 2016 NICE guidance for treating psychosis and schizophrenia in children and young people recommended aripiprazole as a second line treatment after risperidone for people between 15 and 17 who are having an acute exacerbation or recurrence of psychosis or schizophrenia.[2] A 2014 NICE review of the depot formulation of the drug found that it might have a role in treatment as an alternative to other depot formulations of second generation antipsychotics for people who have trouble taking medication as directed or who prefer it.[3]

Adverse effects

See also: List of adverse effects of aripiprazole

In adults, side effects with greater than 10% incidence include weight gain, headache, akathisia, insomnia, and gastro-intestinal effects like nausea and constipation, and lightheadedness.[4][5][6][7][8] Side effects in children are similar, and include sleepiness, increased appetite, and stuffy nose.[7] A strong desire to gamble, binge eat, shop, and engage in sexual activity may also occur.[9][10]

Uncontrolled movement such as restlessness, tremors, and muscle stiffness may occur.[7]

There seems to be no recreational ways for using aripiprazole.

  1. ↑ http://dailymed.nlm.nih.gov/dailymed/lookup.cfm?setid=c040bd1d-45b7-49f2-93ea-aed7220b30ac
  2. ↑ "Psychosis and schizophrenia in children and young people: recognition and management | Guidance and guidelines | NICE". NICE. October 2016. 
  3. ↑ "Schizophrenia: aripiprazole prolonged-release suspension for injection | Guidance and guidelines | NICE". NICE. 24 July 2013. 
  4. ↑ Cite error: Invalid <ref> tag; no text was provided for refs named DM
  5. ↑ Cite error: Invalid <ref> tag; no text was provided for refs named EMC
  6. ↑ Cite error: Invalid <ref> tag; no text was provided for refs named EMA
  7. ↑ 7.0 7.1 7.2 Cite error: Invalid <ref> tag; no text was provided for refs named ABILIFY
  8. ↑ Cite error: Invalid <ref> tag; no text was provided for refs named WebMD
  9. ↑ "Aripiprazole (Abilify, Abilify Maintena, Aristada): Drug Safety Communication - FDA Warns About New Impulse-control Problems". U.S. Food and Drug Administration (FDA). 3 May 2016. Retrieved 4 May 2016. 
  10. ↑ Grall-Bronnec M, Sauvaget A, Perrouin F, Leboucher J, Etcheverrigaray F, Challet-Bouju G, et al. (February 2016). "Pathological Gambling Associated With Aripiprazole or Dopamine Replacement Therapy: Do Patients Share the Same Features? A Review". Journal of Clinical Psychopharmacology. 36 (1): 63–70. doi:10.1097/JCP.0000000000000444. PMC 4700874 Freely accessible. PMID 26658263. 
Retrieved from "https://psy.st/index.php?title=Talk:Aripiprazole&oldid=196840"